Cargando…
Evaluation of the Cost-effectiveness of Services for Schizophrenia in the UK Across the Entire Care Pathway in a Single Whole-Disease Model
IMPORTANCE: The existing economic models for schizophrenia often have 3 limitations; namely, they do not cover nonpharmacologic interventions, they report inconsistent conclusions for antipsychotics, and they have poor methodologic quality. OBJECTIVES: To develop a whole-disease model for schizophre...
Autores principales: | Jin, Huajie, Tappenden, Paul, MacCabe, James H., Robinson, Stewart, Byford, Sarah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254180/ https://www.ncbi.nlm.nih.gov/pubmed/32459356 http://dx.doi.org/10.1001/jamanetworkopen.2020.5888 |
Ejemplares similares
-
A systematic review of whole disease models for informing healthcare resource allocation decisions
por: Jin, Huajie, et al.
Publicado: (2023) -
Systematic review of the methods of health economic models assessing antipsychotic medication for schizophrenia
por: Jin, Huajie, et al.
Publicado: (2020) -
Stratified medicine in schizophrenia: how accurate would a test of drug response need to be to achieve cost-effective improvements in quality of life?
por: Jin, Huajie, et al.
Publicado: (2019) -
Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia
por: McQueen, Grant, et al.
Publicado: (2019) -
41. RECONSIDERING THE EVIDENCE FOR CLOZAPINE FOR TREATMENT REFRACTORY SCHIZOPHRENIA
por: MacCabe, James
Publicado: (2018)